Stallergenes SA, a biopharmaceutical laboratory, engages in the research, development, manufacture, and marketing of allergen immunotherapy medicines in France and internationally. The company offers sublingual products, such as Staloral and Oralair containing allergen extracts; and subcutaneous products, including Alustal and Phostal injectable suspensions containing allergen extracts, as well as Albey and Alyostal hymenoptera venoms. It also provides other diagnostic products, such as Alyostal Pricks, a Glycero-saline solution for IR-IC/ml prick test; Alyostal intra-dermal-reaction powder and solvent for intra-dermal-test solution; Alyostal nasal provocation test powder and solvents; Alyostal conjunctival provocation test powder and diluents; Trolab, a pre-filled syringes for cutaneous applications; and True Test, a transdermal device to aid diagnosis of allergens that cause contact dermatitis. In addition, the company offers medical devices comprising Stallerpoint and Pricks lancet devices for prick tests; and NIOX MINO device to evaluate allergic airway inflammation in patients with underlying asthma. It offers its products in injectable, liquid sublingual, and solid sublingual forms in approximately 23 countries. The company has partnership agreement with DBV Technologies, ActoGeniX, Shionogi & Co. Ltd, and Greer Laboratories Inc. Stallergenes SA was founded in 1962 and is headquartered in Antony, France.